ONESOURCE
ONESOURCE SPECL PHARMA L
Each stock's 10,000-path forecast, rendered as light.
ONESOURCE SPECL PHARMA L (ONESOURCE) Stock Analysis & Case Study
Is ONESOURCE a good buy? The data-driven verdict.
ONESOURCE SPECL PHARMA L (ONESOURCE) trades at ₹1,615,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 19/100.
On the numbers, ONESOURCE SPECL PHARMA L (ONESOURCE) high-risk on the numbers, a Downstox Snapshot Score of 19/100, weighing expensive at 509.0× earnings, ROE of -1.1%, a 36% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
ONESOURCE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is ONESOURCE overvalued? ONESOURCE P/E vs its sector
ONESOURCE's P/E of 509.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers.
ONESOURCE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.4y of ONESOURCE history (-4%/yr drift, 47%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ONESOURCE 2027 | ₹753 | ₹1,364 | ₹2,484 | -15% |
| ONESOURCE 2028 | ₹499 | ₹1,168 | ₹2,692 | -27% |
| ONESOURCE 2029 | ₹363 | ₹1,001 | ₹2,735 | -38% |
| ONESOURCE 2030 | ₹263 | ₹853 | ₹2,820 | -47% |
| ONESOURCE 2031 | ₹195 | ₹728 | ₹2,756 | -55% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ONESOURCE goes up, or doubles?
The bull case for ONESOURCE
- ONESOURCE SPECL PHARMA L is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,735.
The bear case & risks
- A rich 509.0× P/E leaves a thin margin of safety if growth slows.
- A low Piotroski F-Score of 2/9 flags weaker financial health this cycle, worth understanding why before committing.
- The probability model is cautious 12 months out, only a 36% chance of finishing above today's price.
- High historical volatility (47%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹363.
ONESOURCE volatility & expected range, how bumpy is the ride?
Over the last 1.4 years ONESOURCE compounded at -4%/year with annualized volatility of 47%. That volatility implies a 1-year 80% range of ₹753–₹2,484, the honest backbone behind any single price target.
ONESOURCE price forecast, the full 60-month probability fan
ONESOURCE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ONESOURCE hits common targets within the simulated horizon?
Full multi-horizon detail on the ONESOURCE price target & forecast page.
ONESOURCE Piotroski F-Score: 2/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. ONESOURCE scores 2/9,weak on the financial-strength checks.
ONESOURCE MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy ONESOURCE with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 34.9% | 2.9× |
| ZerodhaCHEAPEST | 34.9% | 2.9× |
| Dhan | 35.0% | 2.9× |
Compare every broker on the ONESOURCE MTF page.
ONESOURCE vs peers,sector comparison
About ONESOURCE SPECL PHARMA L: sector, index & market-cap context
ONESOURCE SPECL PHARMA L (ONESOURCE) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹18,527 Cr. See more Nifty 200 stocks.
How the ONESOURCE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of ONESOURCE SPECL PHARMA L's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ONESOURCE analysis, FAQs
Is ONESOURCE SPECL PHARMA L (ONESOURCE) a good buy?
On the numbers, ONESOURCE SPECL PHARMA L (ONESOURCE) high-risk on the numbers, a Downstox Snapshot Score of 19/100, weighing expensive at 509.0× earnings, ROE of -1.1%, a 36% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ONESOURCE overvalued or undervalued?
ONESOURCE trades at 509.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the ONESOURCE share price target for 2031?
ONESOURCE's probability-weighted 2031 median target is ₹728, with an 80% range of ₹195–₹2,756 (10,000-path Monte-Carlo).
What is the probability ONESOURCE doubles in 5 years?
The modelled probability of ONESOURCE reaching ₹3,217 (2×) within 5 years is 8%.
What is the bull case for ONESOURCE?
ONESOURCE SPECL PHARMA L is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in ONESOURCE?
A rich 509.0× P/E leaves a thin margin of safety if growth slows. A low Piotroski F-Score of 2/9 flags weaker financial health this cycle, worth understanding why before committing. The probability model is cautious 12 months out, only a 36% chance of finishing above today's price.